The utility of "routine" chest radiographs, including those for hospital admission and preoperative evaluation, has been examined for several decades in many different settings.'122 No consensus yet exists as to its effectiveness. In 1955, Loderl reviewed 1,000 consecutive preoperative chest radiographs and concluded that the examination was valuable. He did not address cost concerns but quanitified outcome in terms of frequency of findings significant to the anesthesiologist. Beginning in 1973, more frequent reports were published demonstrating that in certain patient populations the preopetative chest radiograph had limited or no utility and should be discontinued. Such recommendations have been made for pediatric patients,24 younger (less than 60 years of age), otherwise healthy, nonsmokers,5-6 and women undergoing preoperative assessment for gynecologic surgery for benign disease.7
pital of the University of Pennsylvania, 3400 ent difficulty in assessing the impact on patient management of outcome based solely on findings from a diagnostic imaging study.
Most of these prior investigations have assessed fairly heterogeneous patient populations, and conclusions often cannot be applied to specific groups or individuals. We have undertaken a pilot evaluation of the role of "routine" preoperative chest radiographs in a population of patients with prostatic carcinoma detected in a screening program. Our intention was not merely to quantify the incidence of abnormal findings, but to attempt to ascertain their impact. In addition, a cost-effectiveness model was used to assess the value of "routine" chest radiography in this specific patient population.
PATIENTS AND METHODS

Patient Population
From June 1989 through April 1992, 497 patients were diagnosed with prostatic carcinoma as part of a prospective study of prostate specific antigen (PSA) screening for prostatic carcinoma. Early results from this study already have been published. 23 As part of their postdiagnosis/preoperative evaluation, all patients were referred for CT of the abdomen and pelvis, radionuclide bone scintigraphy, and standard chest radiography. Two hundred ninety-two patients had retrievable charts with original chest radiograph reports and formed the basis for our evaluation. Almost all of the remaining 205 patients had follow-up evaluations at a different institution or, much less commonly, unretrievable or incomplete charts. All patients did not have acute chest symptoms.
Radiologic Report Review
All original chest radiographic interpretations were classified into five groups. All reports were generated by board-certified radiologists. The studies, themselves, were not reviewed again, since our purpose was to investigate outcome changes and not technical efficacy. If no significant abnormality was detected, the examination was labeled as normal for purposes of this study. Reports overall costs when a patient has been diverted from surgery by the costs of that surgery (minus the cost from any alternative treatment option). Effectiveness, in contradistinction, is much more difficult to quantify. We have implied effectiveness when a true-positive was identified and a definite impact on outcome was perceived.
There are four assumptions inherent in this approach: (1) Cost accounting (appendix A). (2) Patients with a life expectancy of less than 10 years are not candidates for surgery and are believed to benefit similarly or better from a nonsurgical approach (hormonal therapy, radiation therapy, or observation). This assumption, while not universally accepted, is the general consensus among physicians dealing with prostatic carcinoma.24 ( The mean age for all patients with abnormal (groups A through D) chest radiographs was 69.6 years, with a SD of 5.5 years. This was a statistically significant difference when compared with normal subjects, with a mean age of 66.6 years and a SD of 5.5 years (p<0.01). Studies Required for Follow-up These included five CT examinations of the thorax. Three patients had repeat standard chest radiographs, one with nipple markers. One patient had rib detail radiographs.
In addition to these radiologic procedures, two patients had a surgical biopsy of the ribs, and metastatic neoplasm was the suspected finding. applies to two patients: one with lymphoma and one with bronchoalveolar cell carcinoma. We excluded the patient with a group A finding who had a bone metastasis detected on the chest radiograph, since this finding also was detected on a radionuclide bone scintigraph. One of the two patients avoided RRP. Since he was asymptomatic at presentation, it is assumed that had widening of the mediastinum (subsequently proven to be due to lymphoma) not been detected this patient would have undergone a RRP and potentially suffered unnecessary morbidity and mortality. The other benefit to these patients is in the earlier detection of potentially (and proven in one patient) lethal disease processes. In analyzing the remaining abnormal chest radiographic interpretations from our series, no direct benefit could be ascertained. Economic 
We have quantified findings in a relatively homogeneous patient population and have shown, like others before,1'3'6 that routine chest radiography has a relatively low yield in the asymptomatic patient. Only 43 of 292 patients (15 percent) had positive chest radiographic findings. Two of these patients had findings that impacted on the management of the disease and treatment. A patient with bronchoalveolar cell carcinoma underwent successful lobectomy and subsequent RRP. A patient with lymphoma was diverted from a RRP with its accompanying morbidity and cost. Although not unexpected, we have observed that abnormal chest radiographs, occur significantly more frequently with advancing age.
From a strict cost analysis, our program (the use of chest radiographs preoperatively in prostate carcinoma) would cost approximately $2,000 (based on Medicare reimbursement) to $14,000 (based on charges). We have purposely chosen low-cost numbers for the surgical costs and high-cost numbers for the radiologic studies to strengthen any potential claim to cost-effectiveness of the chest radiograph. If it were required that a program be cost-saving in order to be cost-effective, then we could not conclude from our initial assessment that the preoperative chest radiograph is cost-effective. As emphasized earlier, effectiveness is difficult to quantify. Given the morbidity (as well as cost) associated with RRP, one could argue that the impact of any positive radiograph is significant. Even in our small series, it is clear that a significant health benefit is definable, though applicable to only two patients.
In addition, it is important to recognize that not all abnormal chest radiographic findings will be followed up. Patients in our study had findings, such as pulmonary nodules, that potentially could have affected management. Referring clinicians incorporate other factors, such as age, history, and patient preference into their decision to evaluate these findings. It is impossible to assess the cost-effectiveness or even clinical impact of these radiographic findings (group B and C) because of the retrospective nature of our study. Conceivably these findings may have impacted in some way on a decision to divert a patient from surgery, and our assessment may be underestimating the impact of the chest radiograph.
Another potential benefit associated with the use of the preoperative chest radiograph is its utility as a baseline in study, we do not believe this represents a significant source of bias. The vast majority of patients without follow-up were patients who chose to follow-up their prostatic carcinoma diagnosis at a different institution. There is no indication that this group should be different from our study group.
In conclusion, we have investigated the value of the preoperative chest radiograph in patients with prostatic carcinoma diagnosed as part of a screening study, who could be expected to have a low incidence of advanced disease. Such was the case according to the final staging. In our study, the chest radiograph had no impact on final prostatic carcinoma staging, and its only potential value would be as part of preoperative planning and management. Our findings suggest that a small (in terms of number of patients) but significant benefit (detection of asymptomatic comorbid disease and avoidance of unnecessary surgery) was achieved at a cost in the range of $2,000 to $14,000. Because of the limited size of our sample and the difficulty in assessing benefit, retrospectively, we cannot conclude that the preoperative chest radiograph is cost-effective. In addition, the limited size of our sample limits the ability to determine other predictors of comorbid disease. We suggest that our results warrant a larger prospective study of the value of preoperative chest radiography in this era of health care reform. We have obtained all figures listed later from the various departments at Barnes Hospital. Medicare reimbursements are similarly listed and include the 20 percent copayment whenever applicable. To strengthen any claim to cost-effectiveness, we have chosen low-cost numbers for the surgical side of the equation and high-cost numbers for the radiologic side whenever ranges were submitted. Also, additional charges to the surgical side, including consultants' fees, home nursing care, and postoperative complication management, have been disregarded for the purpose of this evaluation. Applying the same model used in our paper and applying it to charges instead of Medicare reimbursements yields the following. The cost of the imaging workup would be $33,000 as noted. The surgical savings would be $19,046. The total cost of the program, then, would be $ 13,954.
